Cassava (SAVA) Stock Falls 30% on Report of Criminal Probe

  • Cassava Biosciences (SAVA) stock is tumbling 30% in pre-market trading.
  • The Justice Department has launched a criminal probe of the company, Reuters reported.
  • Some experts have expressed skepticism about the company's potential Alzheimer's drug, and the firm was accused of multiple improprieties by a short seller.
SAVA stock - Cassava (SAVA) Stock Falls 30% on Report of Criminal Probe

Source: Pavel Kapysh /

Cassava Biosciences (NASDAQ:SAVA) stock is tumbling 30% in pre-market trading after Reuters reported today that the Justice Department has launched a criminal probe of the company. The news service cited two unnamed individuals as its sources for the article.

The Allegations and Cassava’s Denial

The investigation will focus on allegations that the firm “manipulated research results for its experimental Alzheimer’s drug,” according to Reuters.

Cassava “vehemently denies any and all allegations of wrongdoing,” a lawyer for the company stated. The same lawyer “neither confirmed nor denied the existence of the Justice Department criminal probe.”

A Very Controversial Drug

Cassava’s drug, simufilam, which the company says is a potential treatment for Alzheimer’s, has been harshly criticized by many experts and commentators.

In April, I wrote that “nine experts” told The New York Times that “there are no outside studies which indicate that simufilam could positively impact Alzheimer’s patients” through the mechanism of action that Cassava has identified. Moreover, Cassava’s concepts are “implausible and contrived.” The newspaper quoted Dr. Thomas Südhof, a Stanford-based neuroscientist, as saying.

Also importantly, multiple scientific journals have retracted studies on Alzheimer’s produced by the company’s key research partner, Hoau-Yan Wang, a medical professor at the City University of New York (CUNY).

SAVA Stock: Explosive Charges by a Short Seller

In November 2021, I noted that a short selling firm called “Quintessential Capital, which [was] shorting SAVA stock” had issued “a very disturbing new report” about Cassava and the clinical trials of simufilam.

According to Quintessential, Cassava altered subjects’ “initial cognitive scores” and excluded individuals from participating in studies without giving valid reasons for doing so. All while the company directly selected all the subjects used in the trials of its drug. Additionally, Quintessential alleged that a number of trials of simufilam were supervised by multiple people who had been accused of serious improprieties in the past.

After reading about the charges, I wrote that “until the company refutes most or all of the allegations contained in the report, I believe that it’s too risky to hold more than a very small amount of Cassava’s shares.”

In late April 2022, after The Times article was published, despite my earlier bullishness on Cassava, I sold all of my shares of SAVA stock and was urging everyone else to do the same.

I concluded my column by warning that “the unusual nature of the scientists’ charges against Cassava, along with the disturbing report by short seller Quintessential Capital last year, make SAVA stock far too risky for any investor to own.”

On the date of publication, Larry Ramer did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been GE, solar stocks, and Snap. You can reach him on StockTwits at @larryramer.

Article printed from InvestorPlace Media,

©2022 InvestorPlace Media, LLC